Section of Neonatology, Department of Pediatrics, Texas Children's Hospital & Baylor College of Medicine, Houston, TX 77030, USA.
Expert Rev Anti Infect Ther. 2013 Jul;11(7):695-707. doi: 10.1586/14787210.2013.811927.
Neonatal sepsis and necrotizing enterocolitis (NEC) are associated with significant mortality and morbidity. Inflammation secondary to sepsis and NEC increases morbidity, especially those related to the lung, brain and eye. Therapeutic strategies that target inflammation and decrease the emergence of antibiotic resistance are urgently needed. Lactoferrin (Lf) is a multifunctional protein that modulates inflammation, cell growth and differentiation and has broad antimicrobial activity. Studies evaluating the efficacy and safety of Lf in the prevention of neonatal sepsis and NEC are currently in progress, and one completed study shows significant promise. In this article, the functions of this multifunctional molecule and current clinical evidence for its use in the newborn are reviewed. Lf prophylaxis and therapy may have a significant impact in improving clinical outcomes of vulnerable preterm neonates.
新生儿败血症和坏死性小肠结肠炎（NEC）与较高的死亡率和发病率相关。败血症和 NEC 引起的炎症会增加发病率，尤其是与肺、脑和眼相关的发病率。因此，迫切需要针对炎症并降低抗生素耐药性出现的治疗策略。乳铁蛋白（Lf）是一种多功能蛋白，可调节炎症、细胞生长和分化，并且具有广泛的抗菌活性。目前正在进行评估 Lf 在预防新生儿败血症和 NEC 中的疗效和安全性的研究，其中一项已完成的研究显示出了很大的希望。本文回顾了这种多功能分子的功能以及其在新生儿中的临床应用证据。Lf 预防和治疗可能会对改善脆弱早产儿的临床结局产生重大影响。
